Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects
The PACIFIC trial uncovered a new era of immunotherapy in the multi-disciplinary treatment of unresectable locally advanced non-small cell lung cancer (LA-NSCLC), but also proposed a new question of how to further optimize radiotherapy and chemotherapy, in order to maximize synergistic effects with...
Main Author: | YU Silai, NI Jianjiao, ZHU Zhengfei |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Office of China Oncology
2022-06-01
|
Series: | Zhongguo aizheng zazhi |
Subjects: | |
Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1658380577164-1327402352.pdf |
Similar Items
-
The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?
by: Sabrina Rossi, et al.
Published: (2023-12-01) -
Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
by: Xiaofei Zhang, et al.
Published: (2023-02-01) -
Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study
by: Amanda M. Moore, et al.
Published: (2023-09-01) -
Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
by: Huanhuan Li, et al.
Published: (2023-08-01) -
Chemotherapy: A partnership with immunotherapy in non‐small cell lung cancer
by: Ana Sofia Mendes, et al.
Published: (2023-02-01)